Leukemia, Myelogenous, Chronic, BCR-ABL Positive

"Leukemia, Myelogenous, Chronic, BCR-ABL Positive" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure, which enables searching at various levels of specificity.

MeSH information

Definition | Details | More General Concepts | Related Concepts | More Specific Concepts

Clonal hematopoetic disorder caused by an acquired genetic defect in PLURIPOTENT STEM CELLS. It starts in MYELOID CELLS of the bone marrow, invades the blood and then other organs. The condition progresses from a stable, more indolent, chronic phase (LEUKEMIA, MYELOID, CHRONIC PHASE) lasting up to 7 years, to an advanced phase composed of an accelerated phase (LEUKEMIA, MYELOID, ACCELERATED PHASE) and BLAST CRISIS.

Descriptor ID	D015464
MeSH Number(s)	C04.557.337.539.250 C15.378.190.636.370
Concept/Terms	Leukemia, Myelogenous, Chronic, BCR-ABL Positive Leukemia, Myelogenous, Chronic, BCR-ABL Positive Leukemia, Chronic Myelogenous Leukemia, Chronic Myeloid Leukemia, Granulocytic, Chronic Leukemia, Myelocytic, Chronic Leukemia, Myelogenous, Chronic Leukemia, Myelogenous, Ph1 Positive Leukemia, Myelogenous, Ph1-Positive Leukemia, Myeloid, Chronic Leukemia, Myeloid, Ph1 Positive Leukemia, Myeloid, Ph1-Positive Leukemia, Myeloid, Philadelphia Positive Leukemia, Myeloid, Philadelphia-Positive Myelocytic Leukemia, Chronic Chronic Myelocytic Leukemia Chronic Myelocytic Leukemias Leukemia, Chronic Myelocytic Leukemias, Chronic Myelocytic Myelocytic Leukemias, Chronic Myelogenous Leukemia, Chronic Chronic Myelogenous Leukemia Chronic Myelogenous Leukemias Leukemias, Chronic Myelogenous Myelogenous Leukemias, Chronic Myelogenous Leukemia, Ph1-Positive Leukemia, Ph1-Positive Myelogenous Leukemias, Ph1-Positive Myelogenous Myelogenous Leukemia, Ph1 Positive Myelogenous Leukemias, Ph1-Positive Ph1-Positive Myelogenous Leukemia Ph1-Positive Myelogenous Leukemias Myeloid Leukemia, Chronic Chronic Myeloid Leukemia Chronic Myeloid Leukemias Leukemias, Chronic Myeloid Myeloid Leukemias, Chronic Myeloid Leukemia, Ph1-Positive Leukemia, Ph1-Positive Myeloid Leukemias, Ph1-Positive Myeloid Myeloid Leukemia, Ph1 Positive Myeloid Leukemias, Ph1-Positive Ph1-Positive Myeloid Leukemia Ph1-Positive Myeloid Leukemias Myeloid Leukemia, Philadelphia-Positive Leukemia, Philadelphia-Positive Myeloid Leukemias, Philadelphia-Positive Myeloid Myeloid Leukemia, Philadelphia Positive Myeloid Leukemias, Philadelphia-Positive Philadelphia-Positive Myeloid Leukemia Philadelphia-Positive Myeloid Leukemias Granulocytic Leukemia, Chronic Chronic Granulocytic Leukemia Chronic Granulocytic Leukemias Granulocytic Leukemias, Chronic Leukemia, Chronic Granulocytic Leukemias, Chronic Granulocytic

Below are MeSH descriptors whose meaning is more general than "Leukemia, Myelogenous, Chronic, BCR-ABL Positive".

Diseases [C]
Neoplasms [C04]
Neoplasms by Histologic Type [C04.557]
Leukemia [C04.557.337]
Leukemia, Myeloid [C04.557.337.539]
Leukemia, Myelogenous, Chronic, BCR-ABL Positive [C04.557.337.539.250]
Hemic and Lymphatic Diseases [C15]
Hematologic Diseases [C15.378]
Bone Marrow Diseases [C15.378.190]
Myeloproliferative Disorders [C15.378.190.636]
Leukemia, Myelogenous, Chronic, BCR-ABL Positive [C15.378.190.636.370]

Below are MeSH descriptors whose meaning is related to "Leukemia, Myelogenous, Chronic, BCR-ABL Positive".

Below are MeSH descriptors whose meaning is more specific than "Leukemia, Myelogenous, Chronic, BCR-ABL Positive".

Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Blast Crisis
Leukemia, Myeloid, Accelerated Phase
Leukemia, Myeloid, Chronic-Phase

publications

Timeline | Most Recent

This graph shows the total number of publications written about "Leukemia, Myelogenous, Chronic, BCR-ABL Positive" by people in this website by year, and whether "Leukemia, Myelogenous, Chronic, BCR-ABL Positive" was a major or minor topic of these publications.

Bar chart showing 15 publications over 11 distinct years, with a maximum of 3 publications in 2004

To see the data from this visualization as text, click here.

Year	Major Topic	Minor Topic	Total
1997	0	1	1
1998	1	0	1
2004	2	1	3
2007	0	1	1
2009	1	0	1
2010	1	0	1
2014	2	0	2
2015	1	0	1
2016	0	1	1
2020	0	1	1
2022	2	0	2

Below are the most recent publications written about "Leukemia, Myelogenous, Chronic, BCR-ABL Positive" by people in Profiles.

Milojkovic D, Reynolds CJ, Sandoval DM, Pieper FP, Liu S, Pade C, Gibbons JM, McKnight ?, Loaiza S, Palanicawander R, Innes AJ, Claudiani S, Apperley JF, Altmann DM, Boyton RJ. COVID-19 vaccine boosted immunity against Omicron in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors. Leukemia. 2023 01; 37(1):244-247.

View in: PubMed
Gonzalez MA, Olivas IM, Bencomo-Alvarez AE, Rubio AJ, Barreto-Vargas C, Lopez JL, Dang SK, Solecki JP, McCall E, Astudillo G, Velazquez VV, Schenkel K, Reffell K, Perkins M, Nguyen N, Apaflo JN, Alvidrez E, Young JE, Lara JJ, Yan D, Senina A, Ahmann J, Varley KE, Mason CC, Eide CA, Druker BJ, Nurunnabi M, Padilla O, Bajpeyi S, Eiring AM. Loss of G0/G1 switch gene 2 (G0S2) promotes disease progression and drug resistance in chronic myeloid leukaemia (CML) by disrupting glycerophospholipid metabolism. Clin Transl Med. 2022 12; 12(12):e1146.

View in: PubMed
Bencomo-Alvarez AE, Gonzalez MA, Rubio AJ, Olivas IM, Lara JJ, Padilla O, Orazi A, Corral J, Philipovskiy A, Gaur S, Mulla ZD, Dwivedi AK, Eiring AM. Ethnic and border differences on blood cancer presentation and outcomes: A Texas population-based study. Cancer. 2021 04 01; 127(7):1068-1079.

View in: PubMed
Sopper S, Mustjoki S, White D, Hughes T, Valent P, Burchert A, Gjertsen BT, Gastl G, Baldauf M, Trajanoski Z, Giles F, Hochhaus A, Ernst T, Schenk T, Janssen JJ, Ossenkoppele GJ, Porkka K, Wolf D. Reduced CD62L Expression on T Cells and Increased Soluble CD62L Levels Predict Molecular Response to Tyrosine Kinase Inhibitor Therapy in Early Chronic-Phase Chronic Myelogenous Leukemia. J Clin Oncol. 2017 Jan 10; 35(2):175-184.

View in: PubMed
Oaxaca DM, Yang-Reid SA, Ross JA, Rodriguez G, Staniswalis JG, Kirken RA. Sensitivity of imatinib-resistant T315I BCR-ABL CML to a synergistic combination of ponatinib and forskolin treatment. Tumour Biol. 2016 Sep; 37(9):12643-12654.

View in: PubMed
Burchert A, Saussele S, Eigendorff E, M?ller MC, Sohlbach K, Inselmann S, Sch?tz C, Metzelder SK, Ziermann J, Kostrewa P, Hoffmann J, Hehlmann R, Neubauer A, Hochhaus A. Interferon alpha 2 maintenance therapy may enable high rates of treatment discontinuation in chronic myeloid leukemia. Leukemia. 2015 Jun; 29(6):1331-5.

View in: PubMed
Han L, Zi X, Garmire LX, Wu Y, Weissman SM, Pan X, Fan R. Co-detection and sequencing of genes and transcripts from the same single cells facilitated by a microfluidics platform. Sci Rep. 2014 Sep 26; 4:6485.

View in: PubMed
Schmidt M, Rinke J, Sch?fer V, Schnittger S, Kohlmann A, Obstfelder E, Kunert C, Ziermann J, Winkelmann N, Eigendorff E, Haferlach T, Haferlach C, Hochhaus A, Ernst T. Molecular-defined clonal evolution in patients with chronic myeloid leukemia independent of the BCR-ABL status. Leukemia. 2014 Dec; 28(12):2292-9.

View in: PubMed
Frietsch JJ, Kastner C, Grunewald TG, Schweigel H, Nollau P, Ziermann J, Clement JH, La Ros?e P, Hochhaus A, Butt E. LASP1 is a novel BCR-ABL substrate and a phosphorylation-dependent binding partner of CRKL in chronic myeloid leukemia. Oncotarget. 2014 Jul 30; 5(14):5257-71.

View in: PubMed
An X, Tiwari AK, Sun Y, Ding PR, Ashby CR, Chen ZS. BCR-ABL tyrosine kinase inhibitors in the treatment of Philadelphia chromosome positive chronic myeloid leukemia: a review. Leuk Res. 2010 Oct; 34(10):1255-68.

View in: PubMed

People

Explore

Similar Concepts

Top Journals